Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.
The company, however, continues to work on a phase 1/2 study of its H5 mRNA flu vaccine for pandemic preparedness.
Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David ...
Health and Human Services Secretary Robert F. Kennedy Jr. revealed his agency will be cutting funding to mRNA development, calling the vaccine technology "ineffective" and claiming it poses more risks ...
In this free webinar, gain insight into the principles of mRNA and LNP technology and their unique advantages for in vivo CAR T-cell development. Attendees will learn how mRNA synthesis, LNP ...
RNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolioCollaboration combines Moderna’s expertise in mRNA technology for ...
mRNA-3927 is an investigational novel mRNA-based therapeutic agent that is composed of two mRNAs encoding for normal human ...
Health and Human Services Secretary Robert F. Kennedy Jr.’s decision to terminate nearly $500 million in government funding for mRNA vaccine development has alarmed public health experts. “This is a ...
Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.
(TNND) — Health Secretary Robert F. Kennedy Jr.'s decision to terminate nearly $500 million in government funding for mRNA vaccine development has alarmed public health experts. “This is a deeply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results